Distinguished in Hemophilia B

Dr. Doris V. Quon

Hematology
Providence
403 West Adams Boulevard, 
Los Angeles, CA 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Distinguished in Hemophilia B
Providence
403 West Adams Boulevard, 
Los Angeles, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Doris Quon is a Hematologist in Los Angeles, California. Dr. Quon is rated as a Distinguished provider by MediFind in the treatment of Hemophilia B. Her top areas of expertise are Hemophilia A, Blood Clots, Hemophilia B, and Hemophilic Arthropathy. Dr. Quon is currently accepting new patients.

Her clinical research consists of co-authoring 56 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 11 articles and participated in 6 clinical trials in the study of Hemophilia B.

Specialties
Hematology
Licenses
Internal Medicine in CA
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
LA Care
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MercyCare
  • EPO
  • HMO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Sentara Healthcare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE ASSISTANCE PROGRAM
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 14 Less Insurance Carriers -

Locations

403 West Adams Boulevard, Los Angeles, CA 90007
Call: 213-741-8325

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

Safety of SEVENFACT® for the Treatment of Bleeding Events in Patients With Hemophilia A or B With Inhibitors
Safety of SEVENFACT® for the Treatment of Bleeding Events in Patients With Hemophilia A or B With Inhibitors
Enrollment Status: Recruiting
Publish Date: January 12, 2026
Intervention Type: Drug
Study Drug: Coagulation factor VIIa [recombinant]-jncw
Study Phase: Phase 4
A Phase II Trial of ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma Osteosarcoma, Ewing's Sarcoma, and Small Cell Lung Cancer
A Phase II Trial of ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma Osteosarcoma, Ewing's Sarcoma, and Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: December 11, 2025
Intervention Type: Drug, Procedure
Study Drugs: Pegylated arginine deiminase, Gemcitabine, Docetaxel
Study Phase: Phase 2
A Global, Open-Label, Multicenter, Phase 1/2 Study of the Safety and Dose Escalation of BAX 888, an Adeno-Associated Virus Serotype 8 (AAV8) Vector Expressing B-Domain Deleted Factor VIII (BDD-FVIII) in Severe Hemophilia A Subjects Administered a Single Intravenous Infusion
A Global, Open-Label, Multicenter, Phase 1/2 Study of the Safety and Dose Escalation of BAX 888, an Adeno-Associated Virus Serotype 8 (AAV8) Vector Expressing B-Domain Deleted Factor VIII (BDD-FVIII) in Severe Hemophilia A Subjects Administered a Single Intravenous Infusion
Enrollment Status: Completed
Publish Date: September 11, 2025
Intervention Type: Drug
Study Drug: BAX-888 Adeno-Associated Virus Serotype 8 Vector B-Domain Deleted Factor VIII Vaccine
Study Phase: Phase 1/Phase 2
Phase III, Open-label, Single-dose, Multi-center, Multinational Trial Investigating a Serotype 5 Adeno-associated Viral Vector Containing the Padua Variant of a Codon-optimized Human Factor IX Gene (AAV5-hFIXco-Padua, AMT-061) Administered to Adult Subjects With Severe or Moderately Severe Hemophilia B
Phase III, Open-label, Single-dose, Multi-center, Multinational Trial Investigating a Serotype 5 Adeno-associated Viral Vector Containing the Padua Variant of a Codon-optimized Human Factor IX Gene (AAV5-hFIXco-Padua, AMT-061) Administered to Adult Subjects With Severe or Moderately Severe Hemophilia B
Enrollment Status: Completed
Publish Date: May 04, 2025
Intervention Type: Genetic, Biological
Study Drug: AMT-061 Adeno-Associated Virus Padua Variant FIX Vaccine
Study Phase: Phase 3
A Phase 1/2 Study Using Nivolumab and ABI-009 for Advanced Sarcoma, Advanced Carcinoma Treated With PD1 Inhibitors, and Tumors With Genetic Mutations Sensitive to mTOR Inhibitors
A Phase 1/2 Study Using Nivolumab and ABI-009 for Advanced Sarcoma, Advanced Carcinoma Treated With PD1 Inhibitors, and Tumors With Genetic Mutations Sensitive to mTOR Inhibitors
Enrollment Status: Completed
Publish Date: February 17, 2025
Intervention Type: Drug, Biological
Study Drugs: Nab-Rapamycin, Nivolumab
Study Phase: Phase 1/Phase 2
A Natural History Cohort Study of the Safety, Effectiveness, and Practice of Treatment for People With Hemophilia
A Natural History Cohort Study of the Safety, Effectiveness, and Practice of Treatment for People With Hemophilia
Enrollment Status: Completed
Publish Date: February 12, 2025
A Phase I, Open-Label, Ascending Dose Study to Assess the Safety and Tolerability of AAV2/6 Factor IX Gene Therapy Via Zinc Finger Nuclease (ZFN) Mediated Targeted Integration of SB-FIX in Adult Subjects With Severe Hemophilia B
A Phase I, Open-Label, Ascending Dose Study to Assess the Safety and Tolerability of AAV2/6 Factor IX Gene Therapy Via Zinc Finger Nuclease (ZFN) Mediated Targeted Integration of SB-FIX in Adult Subjects With Severe Hemophilia B
Enrollment Status: Terminated
Publish Date: July 19, 2024
Intervention Type: Biological
Study Phase: Phase 1
Phase IIb, Open-label, Single-dose, Single-arm, Multi-center Trial to Confirm the Factor IX Activity Level of the Serotype 5 Adeno-associated Viral Vector Containing the Padua Variant of a Codon-optimized Human Factor IX Gene (AAV5-hFIXco-Padua, AMT-061) Administered to Adult Subjects With Severe or Moderately Severe Hemophilia B
Phase IIb, Open-label, Single-dose, Single-arm, Multi-center Trial to Confirm the Factor IX Activity Level of the Serotype 5 Adeno-associated Viral Vector Containing the Padua Variant of a Codon-optimized Human Factor IX Gene (AAV5-hFIXco-Padua, AMT-061) Administered to Adult Subjects With Severe or Moderately Severe Hemophilia B
Enrollment Status: Completed
Publish Date: June 28, 2024
Intervention Type: Genetic
Study Drug: AMT-061 Adeno-Associated Virus Padua Variant FIX Vaccine
Study Phase: Phase 2
An Observational Cohort Study of Long-Term Outcomes of Orthotopic Liver Transplantation in People With Hemophilia
An Observational Cohort Study of Long-Term Outcomes of Orthotopic Liver Transplantation in People With Hemophilia
Enrollment Status: Completed
Publish Date: May 10, 2023
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase III Study With a Long-Term, Open-Label Extension to Evaluate the Efficacy and Safety of TRM-201 (Rofecoxib) in Patients With Hemophilic Arthropathy
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase III Study With a Long-Term, Open-Label Extension to Evaluate the Efficacy and Safety of TRM-201 (Rofecoxib) in Patients With Hemophilic Arthropathy
Enrollment Status: Terminated
Publish Date: October 27, 2022
Intervention Type: Drug
Study Drug: TRM-201
Study Phase: Phase 3
Advate Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method (ADVATE rAHF-PFM): A Phase 4 Study to Determine the Pharmacokinetic Response of Patients Diagnosed With Severe Hemophilia A to Different Doses of ADVATE rAHF-PFM
Advate Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method (ADVATE rAHF-PFM): A Phase 4 Study to Determine the Pharmacokinetic Response of Patients Diagnosed With Severe Hemophilia A to Different Doses of ADVATE rAHF-PFM
Enrollment Status: Completed
Publish Date: June 10, 2021
Intervention Type: Biological
Study Phase: Phase 4
A Phase 1/2a, Open-Label, Multicenter, Dose Escalation Study to Assess the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) Profile of a Long Acting Recombinant FVIIa (MOD-5014) in Adult Men With Hemophilia A or B
A Phase 1/2a, Open-Label, Multicenter, Dose Escalation Study to Assess the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) Profile of a Long Acting Recombinant FVIIa (MOD-5014) in Adult Men With Hemophilia A or B
Enrollment Status: Completed
Publish Date: May 20, 2021
Intervention Type: Drug
Study Phase: Phase 1
View 11 Less Clinical Trials

55 Total Publications

Safety and Use of Eptacog Beta 225 µg/kg in Patients With Haemophilia A or B With Inhibitors.
Safety and Use of Eptacog Beta 225 µg/kg in Patients With Haemophilia A or B With Inhibitors.
Journal: Haemophilia : the official journal of the World Federation of Hemophilia
Published: February 13, 2025
View All 55 Publications
Similar Doctors
Advanced in Hemophilia B
Dr. Edward Gomperts
Hematology
Advanced in Hemophilia B
Dr. Edward Gomperts
Hematology

Children's Hospital Los Angeles

4650 W Sunset Blvd, 
Los Angeles, CA 
 (4.9 miles away)
323-361-2121
Languages Spoken:
English
See accepted insurances

Edward Gomperts is a Hematologist in Los Angeles, California. Dr. Gomperts is rated as an Advanced provider by MediFind in the treatment of Hemophilia B. His top areas of expertise are Acquired Hemophilia, Hemophilia A, Hemophilia B, and Blood Clots.

Lynn R. Kong
Experienced in Hemophilia B
Dr. Lynn R. Kong
Hematology
Experienced in Hemophilia B
Dr. Lynn R. Kong
Hematology

Ventura County Hematology-Oncology Specialization

1700 N Rose Ave, Ste 320, 
Oxnard, CA 
 (52.1 miles away)
805-485-8709
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Offers high-quality, individualized care with compassion. Believes communication and collaboration with patients is the foundation for effective relationships. Through effective education, patients are empowered to partner in their care and achieve their health goals. Dr. Kong is rated as a Distinguished provider by MediFind in the treatment of Hemophilia B. Her top areas of expertise are Paget Disease of the Breast, Breast Cancer, Inflammatory Breast Cancer, and Melanoma.

Experienced in Hemophilia B
Dr. Ilene Weitz
Hematology
Experienced in Hemophilia B
Dr. Ilene Weitz
Hematology

USC Care Medical Group Inc

1441 Eastlake Ave, 
Los Angeles, CA 
 (4.6 miles away)
323-865-3000
Languages Spoken:
English
See accepted insurances

Ilene Weitz is a Hematologist in Los Angeles, California. Dr. Weitz is rated as a Distinguished provider by MediFind in the treatment of Hemophilia B. Her top areas of expertise are Paroxysmal Nocturnal Hemoglobinuria (PNH), Autoimmune Hemolytic Anemia, Atypical Hemolytic Uremic Syndrome (aHUS), Splenectomy, and Bone Marrow Aspiration.

VIEW MORE HEMOPHILIA B DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Quon's expertise for a condition
ConditionClose
  • Elite
  • Blood Clots
    Dr. Quon is
    Elite
    . Learn about Blood Clots.
    See more Blood Clots experts
  • Hemophilia A
    Dr. Quon is
    Elite
    . Learn about Hemophilia A.
    See more Hemophilia A experts
  • Distinguished
  • Adult Soft Tissue Sarcoma
    Dr. Quon is
    Distinguished
    . Learn about Adult Soft Tissue Sarcoma.
    See more Adult Soft Tissue Sarcoma experts
  • Hemophilia B
    Dr. Quon is
    Distinguished
    . Learn about Hemophilia B.
    See more Hemophilia B experts
  • Hemophilic Arthropathy
    Dr. Quon is
    Distinguished
    . Learn about Hemophilic Arthropathy.
    See more Hemophilic Arthropathy experts
  • Advanced
  • Bone Tumor
    Dr. Quon is
    Advanced
    . Learn about Bone Tumor.
    See more Bone Tumor experts
  • Chondrosarcoma
    Dr. Quon is
    Advanced
    . Learn about Chondrosarcoma.
    See more Chondrosarcoma experts
  • Ewing Sarcoma
    Dr. Quon is
    Advanced
    . Learn about Ewing Sarcoma.
    See more Ewing Sarcoma experts
  • Liposarcoma
    Dr. Quon is
    Advanced
    . Learn about Liposarcoma.
    See more Liposarcoma experts
  • Osteosarcoma
    Dr. Quon is
    Advanced
    . Learn about Osteosarcoma.
    See more Osteosarcoma experts
  • Experienced
  • Adenoid Cystic Carcinoma
    Dr. Quon is
    Experienced
    . Learn about Adenoid Cystic Carcinoma.
    See more Adenoid Cystic Carcinoma experts
  • Agranulocytosis
    Dr. Quon is
    Experienced
    . Learn about Agranulocytosis.
    See more Agranulocytosis experts
  • Alveolar Soft Part Sarcoma
    Dr. Quon is
    Experienced
    . Learn about Alveolar Soft Part Sarcoma.
    See more Alveolar Soft Part Sarcoma experts
  • Anemia
    Dr. Quon is
    Experienced
    . Learn about Anemia.
    See more Anemia experts
  • Angiosarcoma
    Dr. Quon is
    Experienced
    . Learn about Angiosarcoma.
    See more Angiosarcoma experts
  • Chordoma
    Dr. Quon is
    Experienced
    . Learn about Chordoma.
    See more Chordoma experts
View All 24 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved

    Request an Appointment

    If you are experiencing a medical emergency, call 9-1-1.

    MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

    Patient Details

    This information is for the patient who will be seen at the appointment.

      Close

      Returning patient? Use your address on file with the provider.

      Insurance Details

      Please provide information of the primary insurance holder as the practice may require this information to schedule.

      Insurance Provider *
      Insurance ProviderClose

      Appointments Details

      Let’s get more information about your appointment.

              0 / 1000
              0 / 1000
              By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.